PGR and breast cancer: Like dual inhibition of estrogen and mTOR or CDK4/6 in recurrent/metastatic ER-α/PgR-positive breast cancer, the possibility of dual inhibition of androgen and mTOR or CDK4/6 is now attracting interest in TNBC.